Participate in Research

Luminesce
Protocol: STUDY00005812
Full Title
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Description
The purpose of this study is to evaluate the effects, good or bad, of subcutaneous (under the skin) injections of satralizumab in combination with current treatment in patients with generalized Myasthenia Gravis.
Compensation: No
Eligibility
Age Group: Adults
Principal Investigator: GIL WOLFE
ClinicalTrials.gov: Open Study
Contact(s)
KARA PATRICK
kpatrick@buffalo.edu
+1 716-829-5037
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions